Search

everythinglearnresearchcommunity

for

Search:↓

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

The combination treatment showed a higher response rate but no significant survival benefits.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Upadacitinib improved multiple immune-related conditions in one patient.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Upadacitinib effectively treats pyoderma gangrenosum.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Entospletinib effectively prevents eye and skin GVHD in mice.

MK-5108 is safe and shows potential against tumors, especially alone.

A group has developed therapies that show promise for treating cancer and various other conditions.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.